> top > docs > PMC:7105881 > spans > 57074-58559 > annotations

PMC:7105881 / 57074-58559 JSONTXT

Annnotations TAB JSON ListView MergeView

LitCovid-PubTator

Id Subject Object Predicate Lexical cue tao:has_database_id
1724 49-57 Species denotes Sars-CoV Tax:694009
1725 62-70 Species denotes Mers-CoV Tax:1335626
1734 706-714 Species denotes MERS-CoV Tax:1335626
1735 1028-1033 Species denotes human Tax:9606
1736 1034-1047 Species denotes coronaviruses Tax:11118
1737 1075-1083 Species denotes SARS-CoV Tax:694009
1738 1088-1096 Species denotes MERS-CoV Tax:1335626
1739 1478-1484 Species denotes humans Tax:9606
1740 816-829 Disease denotes CoV infection MESH:D018352
1741 1458-1474 Disease denotes viral infections MESH:D001102

LitCovid-PD-FMA-UBERON

Id Subject Object Predicate Lexical cue fma_id
T328 298-302 Body_part denotes face http://purl.org/sig/ont/fma/fma24728
T329 463-470 Body_part denotes protein http://purl.org/sig/ont/fma/fma67257
T330 725-732 Body_part denotes protein http://purl.org/sig/ont/fma/fma67257

LitCovid-PD-UBERON

Id Subject Object Predicate Lexical cue uberon_id
T19 298-302 Body_part denotes face http://purl.obolibrary.org/obo/UBERON_0001456

LitCovid-PD-MONDO

Id Subject Object Predicate Lexical cue mondo_id
T274 49-57 Disease denotes Sars-CoV http://purl.obolibrary.org/obo/MONDO_0005091
T275 177-181 Disease denotes SARS http://purl.obolibrary.org/obo/MONDO_0005091
T276 820-829 Disease denotes infection http://purl.obolibrary.org/obo/MONDO_0005550
T277 1075-1083 Disease denotes SARS-CoV http://purl.obolibrary.org/obo/MONDO_0005091
T278 1125-1129 Disease denotes SARS http://purl.obolibrary.org/obo/MONDO_0005091
T279 1458-1477 Disease denotes viral infections in http://purl.obolibrary.org/obo/MONDO_0005108

LitCovid-PD-CLO

Id Subject Object Predicate Lexical cue
T662 142-147 http://purl.obolibrary.org/obo/NCBITaxon_10239 denotes virus
T663 298-302 http://purl.obolibrary.org/obo/UBERON_0001456 denotes face
T664 584-587 http://purl.obolibrary.org/obo/CLO_0051582 denotes has
T665 595-596 http://purl.obolibrary.org/obo/CLO_0001020 denotes a
T666 682-683 http://purl.obolibrary.org/obo/CLO_0001020 denotes a
T667 739-742 http://purl.obolibrary.org/obo/CLO_0051582 denotes has
T668 779-787 http://purl.obolibrary.org/obo/CLO_0001658 denotes activity
T669 1028-1033 http://purl.obolibrary.org/obo/NCBITaxon_9606 denotes human
T670 1107-1108 http://purl.obolibrary.org/obo/CLO_0001020 denotes a
T671 1234-1240 http://purl.obolibrary.org/obo/NCBITaxon_33208 denotes animal
T672 1478-1484 http://purl.obolibrary.org/obo/NCBITaxon_9606 denotes humans

LitCovid-PD-CHEBI

Id Subject Object Predicate Lexical cue chebi_id
T7910 427-436 Chemical denotes adjuvants http://purl.obolibrary.org/obo/CHEBI_60809
T93211 463-470 Chemical denotes protein http://purl.obolibrary.org/obo/CHEBI_36080
T5022 555-562 Chemical denotes epitope http://purl.obolibrary.org/obo/CHEBI_53000
T33587 725-732 Chemical denotes protein http://purl.obolibrary.org/obo/CHEBI_36080

LitCovid-PD-GO-BP

Id Subject Object Predicate Lexical cue
T122 1458-1474 http://purl.obolibrary.org/obo/GO_0016032 denotes viral infections

LitCovid-sentences

Id Subject Object Predicate Lexical cue
T304 0-87 Sentence denotes Potential Challenges and Future Perspectives for Sars-CoV and Mers-CoV Subunit Vaccines
T305 88-261 Sentence denotes Compared with other vaccine types such as inactivated virus and viral-vectored vaccines, SARS and MERS subunit vaccines are much safer and do not cause obvious side effects.
T306 262-527 Sentence denotes However, these subunit vaccines may face some important challenges, mostly arising from their relatively low immunogenicity, which must be combined with appropriate adjuvants or optimized for suitable protein sequences, fragment lengths, and immunization schedules.
T307 528-660 Sentence denotes In addition, structure and epitope-based vaccine design has become a promising strategy to improve the efficacy of subunit vaccines.
T308 661-849 Sentence denotes This is evidenced by a structurally designed MERS-CoV RBD-based protein which has significantly improved neutralizing activity and protection against MERS-CoV infection (Du et al., 2016a).
T309 850-1097 Sentence denotes It is prospected that more structure-guided novel strategies will be developed to improve the overall immunogenicity and efficacy of subunit vaccines against emerging pathogenic human coronaviruses, including those targeting SARS-CoV and MERS-CoV.
T310 1098-1295 Sentence denotes Although a large number of SARS and MERS subunit vaccines have been developed with potent immunogenicity and/or protection in available animal models, virtually all remain in the preclinical stage.
T311 1296-1485 Sentence denotes It is thus expected that one or several of these promising subunit vaccines can be further processed into clinical trials to confirm their immunogenicity against viral infections in humans.

LitCovid-PMC-OGER-BB

Id Subject Object Predicate Lexical cue
T948 49-53 PR:000014459;SP_10 denotes Sars
T949 53-57 SP_10 denotes -CoV
T950 62-70 SP_9 denotes Mers-CoV
T951 142-147 NCBITaxon:10239 denotes virus
T952 152-157 NCBITaxon:10239 denotes viral
T953 158-166 SO:0000440 denotes vectored
T954 177-181 SP_10 denotes SARS
T955 186-190 SP_9 denotes MERS
T956 371-385 BV_15 denotes immunogenicity
T957 427-436 CHEBI:60809;CHEBI:60809 denotes adjuvants
T958 555-562 BV_9 denotes epitope
T959 569-583 BV_26 denotes vaccine design
T960 706-714 SP_9 denotes MERS-CoV
T961 811-819 SP_9 denotes MERS-CoV
T962 952-966 BV_15 denotes immunogenicity
T963 1028-1033 SP_6;NCBITaxon:9606 denotes human
T964 1034-1047 NCBITaxon:11118 denotes coronaviruses
T965 1075-1083 SP_10 denotes SARS-CoV
T966 1088-1096 SP_9 denotes MERS-CoV
T967 1125-1129 SP_10 denotes SARS
T968 1134-1138 SP_9 denotes MERS
T969 1188-1202 BV_15 denotes immunogenicity
T970 1234-1240 NCBITaxon:33208 denotes animal
T971 1435-1449 BV_15 denotes immunogenicity
T972 1458-1463 NCBITaxon:10239 denotes viral
T973 1478-1484 NCBITaxon:9606 denotes humans
T90797 49-53 PR:000014459;SP_10 denotes Sars
T13411 53-57 SP_10 denotes -CoV
T49408 62-70 SP_9 denotes Mers-CoV
T14847 142-147 NCBITaxon:10239 denotes virus
T61890 152-157 NCBITaxon:10239 denotes viral
T8733 158-166 SO:0000440 denotes vectored
T39185 177-181 SP_10 denotes SARS
T93008 186-190 SP_9 denotes MERS
T9588 371-385 BV_15 denotes immunogenicity
T18188 427-436 CHEBI:60809;CHEBI:60809 denotes adjuvants
T50686 555-562 BV_9 denotes epitope
T36724 569-583 BV_26 denotes vaccine design
T10422 706-714 SP_9 denotes MERS-CoV
T93687 811-819 SP_9 denotes MERS-CoV
T95833 952-966 BV_15 denotes immunogenicity
T22346 1028-1033 SP_6;NCBITaxon:9606 denotes human
T65614 1034-1047 NCBITaxon:11118 denotes coronaviruses
T79036 1075-1083 SP_10 denotes SARS-CoV
T84510 1088-1096 SP_9 denotes MERS-CoV
T52772 1125-1129 SP_10 denotes SARS
T46559 1134-1138 SP_9 denotes MERS
T24258 1188-1202 BV_15 denotes immunogenicity
T30015 1234-1240 NCBITaxon:33208 denotes animal
T29132 1435-1449 BV_15 denotes immunogenicity
T1412 1458-1463 NCBITaxon:10239 denotes viral
T23607 1478-1484 NCBITaxon:9606 denotes humans